BTG   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: London United Kingdom (1991)
Status: Acquired by Boston Scientific Corporation (2018)

Organization Overview

First Clinical Trial
2000
NCT00219791
First Marketed Drug
1993
abiraterone (zytiga)
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Bio-Technology General Israel Ltd. (BTG) | BTG International Inc. | BTG INTERNATIONAL INC | BTG INTL | CellMed AG, a subsidiary of BTG plc. | PROVENSIS